Prosecution Insights
Prosecution Insights
11 pending office actions • 9 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (55%) |
| §102 only | 1 (9%) |
| §112 only | 1 (9%) |
| No statute on record | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIGIL, TORIANA NICHOLE | 1 | 53.2% | +21.4% |
| DONOHUE, SEAN R | 1 | 41.5% | +21.7% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +23.2% |
| WILLIS, DOUGLAS M | 1 | 82.6% | +19.7% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| OUSPENSKI, ILIA I | 1 | 77.6% | +20.3% |
| THUESON, HANNA MARIE | 1 | 71.4% | +30.8% |
| KIM, YUNSOO | 1 | 65.6% | +35.2% |
| FORD, VANESSA L | 1 | 40.1% | +38.3% |
| ALFANO, ALAN | 1 | — | — |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267235 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | WILLIS, DOUGLAS M | 26d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039498 | FORMULATIONS | SCOTLAND, REBECCA LYNN | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18632964 | Imaging Agents | DONOHUE, SEAN R | 81d overdue |
| 18282554 | FORMULATIONS COMPRISING A THERAPEUTIC PROTEIN AND AT LEAST ONE STABILIZER | KWON, JOHN SEUNGJAI | 66d overdue |
| 18152872 | Pharmaceutical Formulations | KIM, YUNSOO | 38d overdue |
| 18045597 | Methods of Treatment Using Anti-IL-17A/F Antibodies | FORD, VANESSA L | 36d overdue |
| 18267235 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | WILLIS, DOUGLAS M | 26d overdue |
| 18703675 | FORMULATIONS | VIGIL, TORIANA NICHOLE | 7d |
| 18021005 | GENE THERAPY USING NUCLEIC ACID CONSTRUCTS COMPRISING METHYL CPG BINDING PROTEIN 2 (MECP2) PROMOTER SEQUENCES | THUESON, HANNA MARIE | 13d |
| 18248651 | BINDING MOLECULES THAT MULTIMERISE CD45 | OUSPENSKI, ILIA I | 33d |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1641 | 2 |
| 1612 | 1 |
| 1618 | 1 |
| 1624 | 1 |
| 1644 | 1 |
| 1638 | 1 |
| 1674 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18703675 | FORMULATIONS | VIGIL, TORIANA NICHOLE | 1612 | Other | Non-Final OA | 7d | Pending | Apr 22, 2024 |
| 18632964 | Imaging Agents | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | 81d overdue | Pending | Apr 11, 2024 |
| 18282554 | FORMULATIONS COMPRISING A THERAPEUTIC PROTEIN AND AT LEAST ONE STABILIZER | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 66d overdue | Pending | Sep 18, 2023 |
| 18267235 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 26d overdue | Pending | Jun 14, 2023 |
| 18039498 | FORMULATIONS | SCOTLAND, REBECCA LYNN | 1615 | §103 | Final Rejection | 5d | Pending | May 31, 2023 |
| 18248651 | BINDING MOLECULES THAT MULTIMERISE CD45 | OUSPENSKI, ILIA I | 1644 | §102 | Non-Final OA | 33d | Pending | Apr 11, 2023 |
| 18021005 | GENE THERAPY USING NUCLEIC ACID CONSTRUCTS COMPRISING METHYL CPG BINDING PROTEIN 2 (MECP2) PROMOTER SEQUENCES | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | 13d | Pending | Feb 13, 2023 |
| 18152872 | Pharmaceutical Formulations | KIM, YUNSOO | 1641 | §103 | Non-Final OA | 38d overdue | Pending | Jan 11, 2023 |
| 18045597 | Methods of Treatment Using Anti-IL-17A/F Antibodies | FORD, VANESSA L | 1674 | Other | Non-Final OA | 36d overdue | Pending | Oct 11, 2022 |
| 17907116 | AUTONOMOUS KNOB DOMAIN PEPTIDES | ALFANO, ALAN | 1641 | §103 | Non-Final OA | 4d overdue | Pending | Sep 23, 2022 |
| 17286247 | METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS | HOLTZMAN, KATHERINE ANN | 1646 | Other | Final Rejection | 80d overdue | Pending | Apr 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial